Physician profile
Nataliya Osorio
NPI 1861009797
$13,123.51
in general payments reported to CMS, 2019-2025
46 companies · $3,804 in 2025
The $3,804 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,184 · 2022: $3,157 · 2023: $3,863 · 2024: $1,115 · 2025: $3,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,902 · Travel and Lodging: $877 · Education: $3.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,901.60 |
| Travel and Lodging | $877.01 |
| Education | $3.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,708.89 | 2021-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $2,607.82 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $1,032.11 | 2023-2025 | Nuplazid |
| Mdd US Operations, LLC | $506.73 | 2022-2025 | Apokyn, Gocovri |
| Teva Pharmaceuticals USA, INC. | $502.14 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Biohaven Pharmaceutical Holding Company Ltd. | $487.44 | 2022 | |
| Biogen, INC. | $480.25 | 2021-2025 | Tysabri, Vumerity |
| Argenx US, INC. | $466.96 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $464.86 | 2021-2025 | Crexont, Rytary |
| Sk Life Science, INC. | $457.73 | 2022-2025 | Xcopri |
| Neurocrine Biosciences, INC. | $270.27 | 2021-2025 | Ongentys, Ingrezza |
| Lundbeck LLC | $241.18 | 2022-2025 | Vyepti, Rexulti |
| Pfizer INC. | $233.55 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.53 | 2022-2023 | Gammagard |
| Biohaven Pharmaceuticals, INC. | $209.36 | 2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nataliya Osorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.